"Having clinical data presentations on multiple product candidates at ASH is reflective of the breadth of TAP compounds now advancing in the clinic," commented Daniel Junius, President and CEO. "While TAP product candidates targeting solid tumors are attracting considerable attention, meaningful progress also is being made with therapies for the treatment of liquid tumors."

Oral Presentation

Abstract: 585 Title: Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) When: Monday, December 7, 2009 at 3:15 pm (CT) Where: R02-R05

Poster Presentations

Abstract: 1862 Title: Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma When: Saturday, December 5, 2009 from 5:30 - 7:30 pm (CT) Where: Hall E, Poster Board I-884

Abstract: 2883 Title: Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis When: Sunday, December 6, 2009 from 6:00 - 8:00 pm (CT) Where: Hall E, Poster Board II-859

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Company's TAP technology uses antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumors. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN901, SAR3419, and BT-062, including risks related to uncertainties around clinical trials conducted and their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and other reports filed with the Securities and Exchange Commission.

SOURCE: ImmunoGen, Inc.

ImmunoGen, Inc. 
Carol Hausner, 781-895-0600 
Executive Director, Investor Relations 
and Corporate Communications 
info@immunogen.com

"Amgen undertook extensive diligence prior to taking the first license that enabled them to move ahead quickly with this second license," said Daniel Junius, President and Chief Executive Officer. "The commitment Amgen is showing to the development of significant new anticancer compounds using our TAP technology is impressive - both in the pace that they took this second license and in their thoroughness around product timelines."

In a release, the Company noted that both licenses were taken under a 2000 agreement that grants Amgen certain rights to test ImmunoGen's maytansinoid TAP technology and to license rights to use it to develop products to individual targets on agreed-upon terms. Under the license announced, ImmunoGen receives a $1 million upfront payment and is entitled to receive milestone payments potentially totaling $34 million plus royalties on the sales of any resulting products. Amgen is responsible for the development, manufacturing and marketing of any products resulting from this license.

((Comments on this story may be sent to health@closeupmedia.com))

Both licenses were taken under a 2000 agreement that grants Amgen certain rights to test ImmunoGen's maytansinoid TAP technology and to license rights to use it to develop products to individual targets on agreed-upon terms. Under the license announced today, ImmunoGen receives a $1 million upfront payment and is entitled to receive milestone payments potentially totaling $34 million plus royalties on the sales of any resulting products. Amgen is responsible for the development, manufacturing and marketing of any products resulting from this license.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's TAP technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to our collaborators, including Amgen, using our technology to develop products, including risks related to uncertainties around product advancement, study findings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and other reports filed with the Securities and Exchange Commission.

SOURCE: ImmunoGen, Inc.

ImmunoGen, Inc. 
Carol Hausner, 781-895-0600 
Executive Director, Investor Relations 
and Corporate Communications 
info@immunogen.com

Both licenses were taken under a 2000 agreement that grants Amgen certain rights to test ImmunoGen's maytansinoid TAP technology and to license rights to use it to develop products to individual targets on agreed-upon terms.

Under the new license, ImmunoGen receives a $1 million upfront payment and is entitled to receive milestone payments potentially totaling $34 million plus royalties on the sales of any resulting products. Amgen is responsible for the development, manufacturing and marketing of any products resulting from this license.

Daniel Junius, president and CEO of ImmunoGen, said: "Amgen undertook extensive diligence prior to taking the first license that enabled them to move ahead quickly with this second license. The commitment Amgen is showing to the development of significant new anticancer compounds using our TAP technology is impressive - both in the pace that they took this second license and in their thoroughness around product timelines."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon